Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene's US NDA Filing for BTK Inhibitor Accepted by FDA

publication date: Aug 26, 2019

Beijing's BeiGene announced its US NDA for the company's BTk inhibitor was accepted by the FDA, its first NDA accepted in the US. The company presented data on zanubrutinib from a China Phase II trial that enrolled 123 MCL patients, along with safety data from 641 patients in five clinical trials for other indications. BeiGene wants to expand the ex-China use of data from China trials to contain clinical costs. The FDA has granted Breakthrough Status for zanubrutinib and will review the candidate under Priority rules. More details....

Stcok Symbol: (NSDQ: BGNE; HKEX: 06160)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital